



JPT 01

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61M 5/30, 25/00		(11) International Publication Number: WO 96/20022 (43) International Publication Date: 4 July 1996 (04.07.96)
<p>(21) International Application Number: PCT/GB95/03016</p> <p>(22) International Filing Date: 21 December 1995 (21.12.95)</p> <p>(30) Priority Data: 9426379.5 23 December 1994 (23.12.94) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): OXFORD BIOSCIENCES LIMITED [GB/GB]; The Magdalen Centre, The Oxford Science Park, Oxford OX4 4GA (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): BELLHOUSE, Brian, John [GB/GB]; The Lodge, North Street, Islip, Oxfordshire OX5 2SQ (GB). BELL, John [CA/GB]; The Dairy, Lower Street, Islip OX5 5SG (GB).</p> <p>(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: PARTICLE DELIVERY</p> <p>(57) Abstract</p> <p>A needless syringe comprising a body containing a lumen, an upstream end of which is, or is arranged to be, connected to a source of gaseous pressure which can suddenly be released into the lumen; the downstream end of the lumen terminating behind a bistable diaphragm which is movable between an inverted position in which it presents outwardly of the body a concavity for containing particles of a therapeutic agent, and an everted, outwardly convex, position; the arrangement being such that, in use, when gas under pressure is released into the lumen, the diaphragm will snap over from its inverted to its everted position and catapult the particles outwardly.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PARTICLE DELIVERY

In our earlier WO94/24263, we disclose a non-invasive drug delivery system involving the use of a needleless syringe which fires particles of a therapeutic agent in controlled doses into body tissue, e.g. through the intact skin, or delivers genetic material into living cells. The syringe described in the earlier application is constructed as an elongate tubular nozzle, a rupturable membrane initially closing the passage through the nozzle adjacent to the upstream end of the nozzle, particles of a therapeutic agent located adjacent to the membrane, and energising means for applying to the upstream side of the membrane a gaseous pressure sufficient to burst the membrane and produce through the nozzle a supersonic gas flow in which the particles are entrained.

As explained in the earlier specification, the particles of the therapeutic agent may be carrier particles coated, for example, with genetic material, or may be powdered drugs for all kinds of therapeutic use. Similarly the earlier specification explains the parameters of particle size (preferably 10-40 μm) density (preferably 0.5-2.0 g/cm^3), and velocity (preferably 200-2500 m/sec), and momentum density (preferably 4-7 $\text{kg}/\text{sec}/\text{m}$), which have been found to be appropriate for adequate target penetration. These parameters are unchanged but we have now devised a modification of the particle delivery system.

According to the present invention, a needleless syringe comprises a body containing a lumen, an upstream end of which is, or is arranged to be, connected to a source of gaseous pressure which can suddenly be released into the lumen; the downstream end of the lumen terminating behind a bistable diaphragm which is movable between an inverted position in which it presents outwardly of the body a concavity for containing particles of a therapeutic agent, and an everted, outwardly convex, position; the arrangement being such that, in use, when gas under

pressure is released into the lumen, the diaphragm will snap over from its inverted to its everted position and catapult the particles outwardly.

This new construction has an advantage that even when,
5 as will be usual, a gaseous supersonic shockwave will be necessary to snap the diaphragm over from its inverted to its everted position, the diaphragm will contain the gas within the lumen so that no provision has to be made for dissipating and silencing any shockwave reflected from the
10 target. Also the target tissue is not subjected to any possibility of harm from the high speed gas flow.

As disclosed in the earlier specification, the release of the pressurized gas may be achieved by building up pressure behind a rupturable membrane until the pressure
15 difference across the membrane is sufficient to rupture the membrane and release the gas suddenly into the lumen. Alternatively the syringe may incorporate a reservoir of compressed gas having a valve which can be opened suddenly to release the gas into the lumen. In both cases, the
20 velocity of the shockwave is increased if the gas is lighter than air, e.g. helium. This effect is enhanced if the lumen is also initially filled with a gas, which is lighter than air, e.g. helium.

In order to avoid loss of particles prior to delivery
25 and to maintain sterility of the particles, the concavity is preferably covered by, for example, a retractable shield or a thin barrier film which is readily penetrated by the particles upon ejection.

The syringe may be constructed for the transdermal
30 delivery of drugs into the body, in which case the lumen may be provided by the passageway through a tubular nozzle, the diaphragm being provided adjacent to the downstream end of the nozzle and facing substantially in the axial direction of the nozzle. Alternatively, the invention may
35 be used in conjunction with a catheter, such as an arterial catheter, in which case the diaphragm may be provided in a sidewall of the catheter body so that upon eversion, the

particles are propelled laterally from the body. This would find use in vascular proliferative diseases for delivering genetic material into the wall of the expanded stenotic blood vessel, to transform genetically the 5 endothelial cells lining the wall of the blood vessel with the aim of preventing subsequent restenosis/re-occlusion of the blood vessel.

Moreover, the development of a catheter-based delivery system may find other uses, as for localised delivery of a 10 combination of compounds (eg for chemotherapy) into specific internal organs and for the local organ-based hormone replacement. The catheter device would also be useful in the administration of drugs or DNA to accessible surfaces for medical purposes (eg for the treatment of 15 tumours of mucosal surfaces, such as respiratory, gastro-intestinal or genito-urinary tracts).

The invention is illustrated by way of example in the accompanying drawings.

Figures 1 to 3 show a syringe for transdermal delivery 20 of particles of therapeutic agent. Thus as particularly shown in Figure 1 the syringe has a cylindrical reservoir 10 initially containing helium under a pressure of about 80 bar. This is screwed and sealed to a first tubular body portion 11 containing a rupture chamber 12. The body 25 portion 11 is screwed and sealed to a second tubular body portion 13 containing a passageway 14. In turn the body portion 13 is screwed and sealed to a third tubular body portion 17 containing a passageway 18, and a tubular tip portion 19 is screwed to the bottom of the body portion 17.

With this construction the reservoir 10 can be stored 30 separately and fitted to the rest of the syringe immediately prior to use. The body portions 11 and 13 are separable to allow the sandwiching between them of a rupturable membrane 20. The tip portion 19 is separable 35 from the body portion 17 to allow the sandwiching between them of an invertible bistable diaphragm 21 which is shaped in the form of a dome from a stiff and strong, but

resilient, material such as Mylar by thermoforming in a suitable jig. The body portions 13 and 17 are separable so that the parts 17, 19 and 21 can be provided as a disposable unit.

5 Particles of therapeutic agent will initially be provided in the concavity at the externally facing surface of the diaphragm 21. The particles may be attached by electrostatic forces, by their natural sticky nature, or by the evaporation of ethanol in which the particles have been
10 suspended. Preferably, however, and for reasons of sterility, the diaphragm 21 is covered and sealed at its edge to a weak barrier film 22 to form a sealed capsule containing the particles 23, as shown in Figure 3. The weak barrier film 22 may be cut or scored to assist rupture
15 and reduce membrane fragmentation.

In use with the syringe assembled and with the lumen 14, 18 prefilled with helium at approximately atmospheric pressure, the tip is placed in proximity to, or in contact with, the skin to be treated and a plunger 24 is depressed
20 to open a valve 25 and allow the helium to be discharged into the rupture chamber 12. This valve 25 may preferably be arranged such that the frontal area of the plunger is greater at the downstream exit to the cylindrical reservoir
25 10 when compared with the upstream frontal area of the plunger, resulting in a self-opening (and quick-opening) valve. When the pressure in the chamber 12 has reached a sufficient value of, for example, about 23 bar, the membrane 20 bursts, releasing a shockwave which propagates through a lumen, i.e. a nozzle, formed by the passageways
30 14 and 18, and causes the diaphragm 21 suddenly to evert into a downwardly, outwardly convex, configuration. This propels the particles 23 rapidly forward out of the syringe with simultaneous rupture of the barrier film 22.

As suggested in Figure 3, a short tubular spacer 26
35 may be provided to reduce the velocity of the particles before impact and to enable the particles to become more spread out in order to increase the target area of skin.

Figures 4 to 7 show the application of the invention to an arterial catheter for use in vascular proliferative disorders.

Figure 5 shows the whole catheter, provided at its upstream end with a reservoir 10, valve 25, rupture chamber 12 and rupturable membrane 20, similar to those of the first example. The catheter may be a triple lumen catheter, one lumen for the usual guidewire, the second to carry gas to inflate a positional balloon 27 for urging a body 28 adjacent to the leading end (shown in Figure 4) of the catheter against a wall of an artery 29, and the third 30 for propagating a shockwave to the tip of the catheter.

At an opening 31 in a sidewall of the catheter body 28, there is provided a bistable diaphragm 32. In a position shown in Figure 4 and in full lines in Figure 6, the diaphragm presents a laterally outwardly facing concavity in which particles of therapeutic agent, such as particles 33, e.g. containing or consisting of DNA, are located. In order to avoid the particles being washed out of the concavity by means of the blood flow in the artery the cavity may initially be covered by a barrier film or by a retractable sleeve 35 as shown in Figure 7.

The catheter is used analogously to the syringe of Figures 1 to 3. Thus release of helium from the reservoir 10 into the rupture chamber 12 eventually bursts the membrane 20 and causes a shockwave to be propagated along the lumen 30 causing the diaphragm 32 to evert suddenly to the dotted line position shown in Figure 6 and hence to propel the particles 33 outwardly, after retraction of the sleeve 35 or through the barrier film, into the wall of the artery 29.

Contrary to what is shown in Figure 6, it may be desirable for the diaphragm 32 to be within the peripheral envelope of the catheter body, not only when in its inverted position in order to avoid interference during insertion of the catheter, but also when in its everted

position to avoid potentially damaging impact with the arterial wall.

CLAIMS

1. A needleless syringe comprising a body (13,17;28) containing a lumen (14,18;30), an upstream end of which is, 5 or is arranged to be, connected to a source (10) of gaseous pressure which can suddenly be released into the lumen; the downstream end of the lumen terminating behind a bistable diaphragm (21,32) which is movable between an inverted position in which it presents outwardly of the body a concavity for containing particles (23,33) of a therapeutic agent, and an everted, outwardly convex, position; the arrangement being such that, in use, when gas under pressure is released into the lumen, the diaphragm will snap over from its inverted to its everted position and catapult the particles outwardly.
15
2. A syringe according to claim 1, wherein the upstream end of the lumen (14,18;30) is initially closed by a rupturable membrane (20) which, when subjected to gas under sufficient pressure is arranged to rupture and release the 20 gas suddenly into the lumen.
3. A syringe according to claim 1 or claim 2, in which the lumen (14,18;30) initially contains a gas which is lighter than air.
4. A syringe according to any one of the preceding 25 claims, in which particles (23,33) of a therapeutic agent are located in the concavity of the inverted diaphragm.
5. A syringe according to claim 4, in which the particles in the concavity are covered by a retractable shield (35).
6. A syringe according to claim 4, in which the particles 30 in the cavity are covered by a thin barrier film (22) which is readily penetrated by the particles upon ejection.
7. A syringe according to any one of the preceding claims, in which the lumen-containing body is a tubular nozzle (14,18), the diaphragm (21) being provided adjacent to the downstream end of the nozzle and facing substantially in the axial direction of the nozzle.
35

8. A syringe according to claim 7, in which a tubular spacer (26) projects from the nozzle downstream of the diaphragm.
9. A syringe according to any one of claims 1 to 6, in
5 which the lumen-containing body is a catheter (28).
10. A syringe according to claim 9, in which the diaphragm (32) is provided in a side wall of the catheter body so that, upon eversion of the diaphragm, the particles (33) are propelled laterally from the body.
11. A product for therapeutic use, the product comprising
10 a unit of or for a syringe according to any one of the preceding claims, the unit comprising a dome-shaped diaphragm in the concave side of which are sealed particles of a therapeutic agent, the diaphragm being arranged suddenly to evert under a gaseous shock-wave applied to the convex side of the dome whereby the particles are catapulted outwardly from the diaphragm.
12. A product according to claim 1, wherein the particles are sealed between the concave side of the diaphragm and a
20 covering barrier film which is sealed to the diaphragm.
13. A method of therapeutic treatment by the injection of particles of therapeutic agent into bodily tissue, the method comprising providing the particles in the concave side of a dome-shaped diaphragm, and applying a gaseous
25 shockwave to the convex side of the dome whereby the dome suddenly everts and catapults the particles outwardly from the diaphragm.

1/2 (Q)

Fig.1.




Fig.2.





Fig.3.



$\frac{2}{2}$

Fig.4.




Fig.5.




Fig.6.




Fig.7.

